DE69929189D1 - Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche - Google Patents

Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche

Info

Publication number
DE69929189D1
DE69929189D1 DE69929189T DE69929189T DE69929189D1 DE 69929189 D1 DE69929189 D1 DE 69929189D1 DE 69929189 T DE69929189 T DE 69929189T DE 69929189 T DE69929189 T DE 69929189T DE 69929189 D1 DE69929189 D1 DE 69929189D1
Authority
DE
Germany
Prior art keywords
afp
fetoprotein
alpha
complex
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929189T
Other languages
English (en)
Other versions
DE69929189T2 (de
Inventor
Oleg Strelchenok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardenia Investments Ltd
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of DE69929189D1 publication Critical patent/DE69929189D1/de
Application granted granted Critical
Publication of DE69929189T2 publication Critical patent/DE69929189T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69929189T 1998-06-17 1999-06-17 Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche Expired - Lifetime DE69929189T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9802162A SE9802162D0 (sv) 1998-06-17 1998-06-17 Immunostimulating composition
SE9802162 1998-06-17
PCT/EP1999/004201 WO1999065936A2 (en) 1998-06-17 1999-06-17 Composition for the treatement of immune deficiencies and methods for its preparation and use

Publications (2)

Publication Number Publication Date
DE69929189D1 true DE69929189D1 (de) 2006-02-02
DE69929189T2 DE69929189T2 (de) 2006-08-31

Family

ID=20411743

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929189T Expired - Lifetime DE69929189T2 (de) 1998-06-17 1999-06-17 Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche

Country Status (11)

Country Link
US (1) US6599507B2 (de)
EP (1) EP1085909B1 (de)
JP (1) JP4392991B2 (de)
AT (1) ATE314094T1 (de)
AU (1) AU748838B2 (de)
BR (1) BR9911294B1 (de)
CA (1) CA2335079C (de)
DE (1) DE69929189T2 (de)
HK (1) HK1035866A1 (de)
SE (1) SE9802162D0 (de)
WO (1) WO1999065936A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
JP4515642B2 (ja) * 1999-03-16 2010-08-04 アーデニア・インベストメンツ・リミテッド 多価不飽和脂肪酸誘導体およびその使用
ATE339429T1 (de) 2000-07-12 2006-10-15 Ardenia Investments Ltd Neue cytotoxische verbindungen und deren verwendung
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096863A (en) * 1996-08-23 2000-08-01 Regents Of The University Of Minnesota Self-assembling amphiphiles for construction of peptide secondary structures
SE9802162D0 (sv) 1998-06-17 1998-06-17 Nomet Management Services Bv Immunostimulating composition

Also Published As

Publication number Publication date
JP2004500315A (ja) 2004-01-08
BR9911294B1 (pt) 2012-01-10
EP1085909A2 (de) 2001-03-28
AU748838B2 (en) 2002-06-13
BR9911294A (pt) 2002-01-02
CA2335079A1 (en) 1999-12-23
US20010034324A1 (en) 2001-10-25
AU4773499A (en) 2000-01-05
JP4392991B2 (ja) 2010-01-06
WO1999065936A2 (en) 1999-12-23
CA2335079C (en) 2008-01-08
EP1085909B1 (de) 2005-12-28
WO1999065936A3 (en) 2000-02-10
ATE314094T1 (de) 2006-01-15
SE9802162D0 (sv) 1998-06-17
US6599507B2 (en) 2003-07-29
HK1035866A1 (en) 2001-12-14
DE69929189T2 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE321525T1 (de) Verwendung von konjugierten linolensaüren zur topischen behandlung von zellulitis
DE60000492D1 (de) Kosmetisches Verfahren zur Haarbehandlung mit Metallpartikeln zur Verbesserung des Haarglanzes
DE69527765T2 (de) Verwendung von Hyaluronsäure oder sein Salz zur Behandlung von Hauterkrankungen
DE59807213D1 (de) 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
DE69840126D1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69031656D1 (de) Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung
DE60212627D1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
DE60216281D1 (de) Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
BG104726A (en) Novel derivatives of the dihydroxyhexanoic acid
DE69804130D1 (de) Verwendung eines gemischs aus einem diol und einer alpha-hydroxysäure zur behandlung hyperkeratotischer hauterkrankungen
DE69734838D1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
ATE172117T1 (de) Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
DE69929189D1 (de) Ein Komplex aus Alpha-Fetoprotein (AFP) und einem polyungesättigten Fettsäurederivat zur Behandlung von Immunschwäche
EP1546182A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
SG147469A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE69130679T2 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE68911693D1 (de) Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung.
DE69838553D1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
DE69003960D1 (de) Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten.
DE60039517D1 (de) Verwendung eines ginkgo extraktes zur behandlung von krebs welcher durch überexpression von peripherem benzodiazepin rezeptor protein gekennzeichnet ist
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ARDENIA INVESTMENTS LTD., LONDON, GB

8364 No opposition during term of opposition